Pharmaceutical Clinical Research Associates (CRAs) are critical members of the drug development team responsible for managing and monitoring clinical trials that test new medications for safety and efficacy. They ensure that trials are conducted in compliance with regulatory standards such as Good Clinical Practice (GCP) and study protocols. CRAs regularly visit clinical trial sites to verify the accuracy of collected data, confirm that patients meet eligibility criteria, and ensure informed consent has been properly obtained. By meticulously reviewing case report forms against source documents, they help maintain data integrity and protect patient safety throughout the study. Their monitoring activities are essential to producing reliable and valid results for regulatory review.
In addition to site monitoring, CRAs serve as a communication link between pharmaceutical sponsors, clinical investigators, and regulatory authorities. They provide ongoing support and training to clinical site personnel to uphold quality standards and regulatory compliance. CRAs also prepare monitoring visit reports and assist in the preparation of documentation required for audits and inspections. Strong attention to detail, excellent organizational skills, and the ability to manage multiple sites are crucial attributes for success in this role. Ultimately, CRAs help ensure that clinical trials are conducted ethically and efficiently, contributing to the development of new therapies that improve patient outcomes globally.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India
Title : Bridging tradition and innovation: Inorganic meets green synthesis
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy